Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
36 filings of NATCOPHARM since November 2024.
board outcome 12, presentation 10, transcript 9, results 2, dividend 2, credit rating 1
| Filed | Type | Subject | |
|---|---|---|---|
| 13 Nov 2026 | presentation Acquisition, Results | Natco Pharma Limited has informed the Exchange about Investor PresentationAI summaryNATCO Pharma filed its Q2 FY27 earnings presentation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, dated 13 November 2026. Consolidated total revenue for Q2 FY27 was INR 10,194 Mn, against INR 14,630 Mn in Q2 FY26 and INR 7,944 Mn in Q1 FY27. EBITDA (including other income) was INR 3,100 Mn, with an EBITDA margin of 30.4% versus 30.9% in Q1 FY27. Profit after share of profit of associate was INR 2,026 Mn, with basic and diluted EPS of INR 11.31 per share. During the quarter the company acquired an additional 13.25% stake in Adcock Ingram Holdings Limited, taking its holding to 49%, and invested a further US$ 16.7 million in eGenesis, Inc., bringing total investment in eGenesis to US$ 24.7 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2026 | board outcome Dividend / buy-back, Results | Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27AI summaryNATCO Pharma Limited's board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with Limited Review Report of the Statutory Auditors. The board declared a second interim dividend of Rs. 1.25 per equity share (62.50%) on a face value of Rs. 2 for FY 2026-27. The record date for the second interim dividend is Thursday, November 19, 2026, and payment will start from November 27, 2026. The board meeting ran from 11:50 a.m. to 2:00 p.m., and a press release was enclosed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Sep 2026 | board outcome Acquisition, Capex, Legal, Management change | Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026.AI summaryBoard of Natco Pharma approved a rights issue of fully paid equity shares of face value ₹2 each for an amount not exceeding ₹1,300 crore, with the record date to be determined later. Board constituted a Fund-Raising Committee comprising V.C. Nannapaneni (Chairman), Rajeev Nannapaneni and P.S.R.K. Prasad, and approved the draft Letter of Offer for the rights issue. On the demerger scheme with Natco Crop Health Sciences Limited, the company has received observation letters from both stock exchanges but has not yet filed the scheme with the NCLT. Board decided to make consequential changes to the scheme after completion of the rights issue, aiming to keep the share swap ratio unchanged, and to file the revised scheme with the stock exchanges later. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Aug 2026 | presentation Acquisition, Results | Natco Pharma Limited has informed the Exchange about Investor PresentationAI summaryNATCO Pharma filed its August 2026 Investor Presentation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements. The presentation reports FY26 global revenues of INR 43,759 million, against INR 20,202 million in FY17, an 8% CAGR over that period. FY26 EBITDA is shown as INR 17,341 million (FY17: INR 6,843 million) and PAT as INR 14,185 million (FY17: INR 4,849 million). The company states it has 5,000+ employees as of March 31, 2026, and that two API and two FDF plants are USFDA approved. The presentation also notes the 2025 acquisition of a 35.75% stake in Adcock Ingram Holdings Limited (South Africa) and an additional 13.25% stake acquired in 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Aug 2026 | transcript Acquisition, Capex, Guidance, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNATCO Pharma filed the transcript of its Q1 FY27 earnings conference call held on August 14, 2026. Management (CFO Amit Parekh) reported consolidated total revenue of INR794.4 crores versus INR1,390.6 crores a year earlier, mainly due to lower Lenalidomide revenue, and EBITDA including other income of INR245.7 crores (30.9% margin). Consolidated PAT was INR206.5 crores; management said the prior-quarter figure of INR269 crores included a one-time deferred tax benefit of INR115 crores. Management said NATCO's share of profit from associate Adcock Ingram was INR84.3 crores, and that it acquired an additional 13.25% stake in July 2026, taking its holding to 49%. Management said net cash was around INR1,400 crores and the company is evaluating acquisitions, which it cited as a reason for a proposed INR2,000 crore fundraise. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | presentation Acquisition, Legal, Results | Natco Pharma Limited has informed the Exchange about PresentationAI summaryNATCO Pharma filed its Q1 FY27 earnings presentation for the quarter ended 30 June 2026. Consolidated total revenue for Q1 FY27 was INR 7,944 Mn, against INR 8,169 Mn in Q4 FY26 and INR 13,906 Mn in Q1 FY26 (figures as printed). EBITDA for Q1 FY27 was INR 2,457 Mn, an EBITDA margin of 30.9%, against 25.1% in Q4 FY26. Profit after tax was INR 2,065 Mn (PAT margin 26.0%), and reported basic and diluted EPS was INR 11.53. The presentation states that profit share from associate Adcock Ingram Holdings Ltd was INR 843 Mn, that NATCO acquired an additional 13.25% stake in Adcock Ingram in July 2026 (taking holding to 49%), and that the company received final US FDA approval for Eribulin Mesylate Injection. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | board outcome Capex, Dividend / buy-back, Legal, Management change, Results | Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27AI summaryBoard outcome for the meeting held 14 August 2026: unaudited standalone and consolidated results for the quarter ended 30 June 2026 approved, with consolidated total revenue of INR 794.4 crore (vs INR 1,390.6 crore a year earlier) and consolidated net profit of INR 206.5 crore (vs INR 480.3 crore). Board declared interim dividend of Rs 1.50 per equity share of Rs 2 each (75%) for FY2026-27; record date 20 August 2026, payment from 26 August 2026. Board approved evaluating raising of up to INR 2,000 crore through equity or other securities, subject to shareholder and regulatory approvals. Board approved the notice for the 43rd Annual General Meeting, to be held through VC/OAVM; date and time to be fixed by the Chairman and Managing Director. Board reconstituted the Risk Management Committee and the ESG Committee with effect from 14 August 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Jul 2026 | board outcome Acquisition, Capex | Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026.AI summaryNATCO Pharma's board approved an investment of up to Rs. 1,400 crores in its wholly owned subsidiary Natco Pharma South Africa Proprietary Limited, to be made in cash. The board also approved acquiring 19,618,825 shares of Adcock Ingram Holdings Proprietary Limited at ZAR 92.50 per share, raising NATCO's holding from 35.75% to 49%. The total cost of the Adcock Ingram stake purchase is ZAR 1,814,741,312.50, about Rs. 1,069 crores at the prevailing exchange rate, excluding certain transaction costs and expenses. The filing states Adcock Ingram delivered a topline of US$ 423 million and EBITDA of about US$ 59 million for the nine months ended March 31, 2026, and that NATCO will recognise 49% of its profit after tax. The acquisition is subject to customary closing conditions and statutory compliances, and the subsidiary investment is expected to complete before the end of July 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Jun 2026 | transcript Acquisition, Dividend / buy-back, Guidance, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryTranscript of NATCO Pharma's Q4 FY26 earnings conference call held May 29, 2026, filed under Regulation 30. Management said consolidated revenue for FY26 was INR4,375.9 crores (vs INR4,784 crores) and net profit INR1,418.5 crores (vs INR1,883.4 crores); Q4 revenue was INR816.9 crores (vs INR1,287.3 crores) and Q4 profit INR269 crores (vs INR406 crores), including a one-time INR115 crores tax benefit. Management guided FY27 revenue of INR3,400-3,500 crores and PAT of INR700-750 crores, with associate Adcock Ingram revenue of $580-600 million and PAT of $47-48 million, subject to exchange rates and war-related factors. Management expects earnings to compound around 15% to 25% a year from FY28, with FY27 as a base year; it cited R&D spend of 7-9% of revenue next year and net cash of about INR2,400 crores at group level. Management said it is looking at one or two large acquisitions but had no update on timing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | presentation Acquisition, Legal, Results | Natco Pharma Limited has informed the Exchange about FY26 Earnings PresentationAI summaryNATCO Pharma filed its Q4 FY26 and FY26 earnings investor presentation for the quarter and year ended 31 March 2026. Q4 FY26: total revenue INR 8,169 Mn, EBITDA INR 2,054 Mn (25.1% margin), profit after tax INR 2,690 Mn (36.4% margin per the presentation's highlights, including a one-time tax benefit of INR 1,150 Mn), EPS INR 14.96. FY26: total revenue INR 43,759 Mn, EBITDA INR 17,341 Mn (39.6% margin), profit after tax INR 14,185 Mn (32.4% margin), EPS INR 79.20. The presentation states the company acquired a 35.75% stake in Adcock Ingram Holdings Limited, South Africa, and lists new US and Indian product launches, including Semaglutide multi-dose vials in India and Pomalidomide capsules in the US. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | board outcome Legal, Results | Natco Pharma Limited has submitted to the Exchange, the Audited financial results for the quarter and year ended March 31, 2026.AI summaryOutcome of board meeting held on 29 May 2026 (meeting 11:45 a.m. to 14:05 p.m.), filed with BSE and NSE. The board approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 under Ind AS and Regulation 33 of the Listing Regulations, with the statutory auditor BS Rand & Co's reports attached; the auditor's consolidated report covers the parent, its subsidiaries and an associate, and the filing declares unmodified audit opinions. The board amended the Corporate Social Responsibility Policy and the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. A copy of the press release was enclosed; the pages provided do not include the figures for revenue or profit. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Mar 2026 | board outcome Acquisition, Capex, Legal | Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on March 24, 2026AI summaryThe Board of NATCO Pharma Limited approved a Scheme of Arrangement under Sections 230-232 of the Companies Act, 2013, demerging its Agrochemicals Undertaking into wholly owned subsidiary Natco Crop Health Sciences Limited, with an appointed date of 1 October 2026. Share entitlement: 1 equity share of INR 2 in the resulting company for every 1 equity share of INR 2 held in NATCO Pharma; NATCO Pharma will retain 20% post-listing shareholding in the resulting company. The Agrochemicals business turnover was INR 60,62,03,918 for FY ended 31 March 2025, which is 1.48% of the company's total turnover. The scheme is subject to approval of shareholders and creditors and of the National Company Law Tribunal, and to no-objection letters from the stock exchanges. The Board also approved incorporating a wholly owned subsidiary in Nigeria, NATCO Pharma Nigeria Limited, with investment up to USD 100,000, and liquidating its wholly owned subsidiary Natco Pharma Australia Pty Ltd. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Feb 2026 | transcript Acquisition, Capex, Dividend / buy-back, Guidance, Legal, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNATCO Pharma filed the transcript of its Q3 and FY26 earnings conference call held on February 12, 2026. Management reported consolidated total revenue of INR705.4 crores for the quarter ended December 31, 2025, against INR651.1 crores a year earlier, EBITDA of INR216.8 crores (30.7% margin) and consolidated net profit of INR151.3 crores. Management declared an interim dividend of INR1.5 per equity share of INR2 each for Q3 FY26. Management said it is not considering a share buyback at this time, preserving cash for another large acquisition, and that it is pursuing 2-3 targets, with the aim of closing at least one in calendar 2026. Management said the Crop Health Sciences de-merger process has started, with an end goal of completion in about 8-9 months, and that GLP-1 (semaglutide) approval is expected this month and is pending with the DCGI. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | board outcome Acquisition | Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026.AI summaryNATCO Pharma's Board approved, at a meeting held on 12 February 2026, incorporating a wholly owned subsidiary in Chile. The proposed subsidiary is named NATCO Pharma Chile SPA, with a proposed line of business in pharmaceuticals. Investment is capped at US$ 3,00,000 (three lakh US dollars), paid in cash, for 100% shareholding. The entity is yet to be incorporated; FEMA and other applicable regulatory approvals in Chile are required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | presentation Acquisition, Capex, Results | Natco Pharma Limited has informed the Exchange about Investor PresentationAI summaryNATCO Pharma filed its Q3 FY26 earnings presentation for the quarter ended 31 December 2025. Consolidated total revenue for Q3FY26 was INR 7,054 Mn (Q3FY25: INR 6,511 Mn); EBITDA was INR 2,168 Mn with a 30.7% margin; net profit was INR 1,513 Mn; reported basic and diluted EPS was INR 8.46. Net profit includes a share of associate profit of INR 109 Mn for 10 Nov to 31 Dec 2025, after a one-time amortisation of INR 187.5 Mn, from the 35.75% stake in Adcock Ingram Holdings Limited, South Africa. Management highlighted the launch of Risdiplam oral solution for Spinal Muscular Atrophy in India and the Adcock Ingram acquisition culminating in Q3FY26. Management reported 9MFY26 profit after tax of INR 11,495 Mn and 9MFY26 EPS of INR 64.24. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | board outcome Acquisition, Capex, Dividend / buy-back, Legal, Management change, Results | Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025 and declaration of 3rd Interim Dividend of Rs.1.50 per share for the fy 2025-26AI summaryBoard outcome for the quarter and nine months ended 31 December 2025: unaudited standalone and consolidated results approved; consolidated revenue from operations Rs 6,473 million for the quarter and Rs 33,392 million for nine months; consolidated profit for the period Rs 1,513 million for the quarter (Rs 11,495 million for nine months). Third interim dividend of Rs 1.50 per equity share (75% on Rs 2 face value) declared; record date 18 February 2026, payment from 26 February 2026. Re-appointment for one year w.e.f. 1 April 2026 of Venkaiah Chowdary Nannapaneni (Chairman & Managing Director), Rajeev Nannapaneni (Vice Chairman & CEO), P. S. Prasad and Dr. Donthineni Linga Rao (Directors), subject to shareholder approval by postal ballot. Amit Parekh appointed Chief Financial Officer w.e.f. 13 February 2026, following superannuation of S. V. V. N. Appa Rao; Kalakuntla Srinivas Rao appointed Executive Vice President – Pharma Division w.e.f. 12 February 2026. Board approved incorporation of a wholly owned subsidiary in Chile (NATCO Pharma Chile SPA) with investment up to US$ 300,000; ESG and Risk Management Committees re-constituted w.e.f. 13 February 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | dividend Acquisition, Dividend / buy-back, Management change, Results | Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on February 12, 2026, declared Interim Dividend of 1.50 per equity share.AI summaryBoard meeting outcome dated 12 February 2026: approved unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2025. Consolidated revenue from operations for Q3 FY26 was Rs 6,473 million, against Rs 4,748 million a year earlier; net profit attributable to owners was Rs 1,515 million, against Rs 1,330 million. Declared third interim dividend of Rs 1.50 per equity share (75% on face value of Rs 2); record date 18 February 2026, payment from 26 February 2026. Re-appointed Venkaiah Chowdary Nannapaneni as Chairman & Managing Director and Rajeev Nannapaneni as Vice Chairman & CEO, among others, for one year from 1 April 2026, subject to shareholder approval by postal ballot. Mr. Amit Parekh appointed CFO from 13 February 2026 after the superannuation of S. V. V. N. Appa Rao; Kalakuntla Srinivas Rao appointed EVP – Pharma Division from 12 February 2026; approved a wholly owned Chile subsidiary (NATCO Pharma Chile SPA) with investment up to US$300,000. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Nov 2025 | credit rating Legal, Rating | Natco Pharma Limited has informed the Exchange about Credit RatingAI summaryNATCO Pharma Limited filed intimation under Regulation 30 of SEBI LODR that ICRA Limited reaffirmed or assigned its credit ratings on November 28, 2025. Ratings on all instruments are [ICRA]AA (Stable) for long-term and [ICRA]A1+ for short-term; the total rated amount rose from Rs. 1,550.00 crore to Rs. 2,150.00 crore. Fund-based working capital limits (Rs. 930.00 crore) and non-fund based working capital limits (Rs. 120.00 crore) were reaffirmed; unallocated limits increased from Rs. 100.00 crore to Rs. 300.00 crore. A new long-term fund-based term loan of Rs. 400.00 crore was assigned; commercial paper of Rs. 400.00 crore was reaffirmed at [ICRA]A1+. ICRA cites healthy financial profile and strong liquidity, despite expected revenue and margin moderation after gRevlimid patent expiry in Q2 FY2026 and a Rs. 2,000 crore payment for a 35.75% stake in Adcock Ingram Holdings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Nov 2025 | transcript Acquisition, Dividend / buy-back, Guidance, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNATCO Pharma filed the transcript of its Q2 FY26 earnings conference call held on November 14, 2025 (quarter ended September 30, 2025). Management said consolidated total revenue was Rs 1,463 crores against Rs 1,434.9 crores a year earlier, EBITDA was Rs 679.2 crores (46.4% margin), and consolidated net profit was Rs 517.9 crores. The board declared an interim dividend of Rs 1.5 per equity share of Rs 2. Management said it is not budgeting much revenue from Lenalidomide for Q3 and Q4 due to increasing competition, expects a run rate of Rs 750-800 crores revenue and PAT of Rs 135-150 crores, and is targeting a demerger and separate listing of the CTPR crop health business in 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Nov 2025 | presentation Results | Natco Pharma Limited has informed the Exchange about PresentationAI summaryNATCO Pharma filed its Q2 FY26 earnings presentation for the quarter and half year ended September 30, 2025. Consolidated total revenue for Q2FY26 was INR 14,630 Mn, against INR 14,349 Mn in Q2FY25 and INR 13,906 Mn in Q1FY26. EBITDA for Q2FY26 was INR 6,792 Mn with an EBITDA margin of 46.4%; profit after tax was INR 5,179 Mn, and basic and diluted EPS was INR 28.94. Net cash as of September 30, 2025 was INR 39,030 Mn; the company notes that the Adcock transaction payout was made in Q3FY26. The presentation also lists Para IV product pipeline filings in the US, and describes investments in cell and gene therapy companies and the NRC-2694 Phase 2 head and neck cancer trial. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Nov 2025 | board outcome Acquisition, Dividend / buy-back, Results | outcome of Board Meeting held on 14th November, 2025AI summaryNATCO Pharma filed the outcome of its board meeting held on November 14, 2025, approving unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025. Consolidated revenue from operations was Rs 13,630 million for the quarter ended September 30, 2025, and Rs 26,919 million for the half year; consolidated profit for the quarter was Rs 5,179 million (Rs 9,982 million for the half year). The board declared a second interim dividend of Rs 1.50 per equity share of Rs 2 each (75%) for FY 2025-26, with record date November 20, 2025 and payment starting November 28, 2025. The board approved incorporating a wholly-owned subsidiary in India to act as the resulting company for the proposed demerger of the Crop Health Sciences Division. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Aug 2025 | transcript Acquisition, Capex, Dividend / buy-back, Guidance, Legal, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNatco Pharma filed the transcript of its Q1 FY26 earnings conference call held on 13 August 2025 (quarter ended 30 June 2025). Management reported consolidated total revenue of INR1,390.6 crores (vs INR1,410.7 crores a year earlier), EBITDA of INR632.7 crores with a 45.5% margin, and consolidated net profit of INR480.3 crores; an interim dividend of INR2 per equity share was declared. Management said the U.S. business faced pricing pressure, mainly on Revlimid, expected to continue into the September quarter and decline thereafter, and that higher other expenses reflect R&D on high-value projects and one-time batch expenses, expected to reduce from the December quarter. Management said NRC-2694 Phase II is ongoing with about 13-14 patients enrolled, and that a meaningful data readout could be around mid-FY27. Management said it may pursue another large transaction similar to the Adcock deal, with the increase in authorized capital being an enabling resolution; cash was INR3,500 crores, which would fall to about INR1,500 crores if a deal of INR2,000 crores were completed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | presentation Results | Natco Pharma Limited has informed the Exchange about Investor PresentationAI summaryNATCO Pharma filed its Q1 FY26 earnings presentation for the quarter ended 30 June 2025, dated 12 August 2025. Consolidated total revenue for Q1FY26 was INR 13,906 Mn (Q1FY25: INR 14,107 Mn; Q4FY25: INR 12,873 Mn), with Pharma Export Formulations at INR 11,265 Mn and Domestic Formulations at INR 1,070 Mn. EBITDA was INR 6,327 Mn with an EBITDA margin of 45.5% (including other income); profit before tax was INR 5,719 Mn and profit after tax was INR 4,803 Mn (PAT margin 34.5%). Basic and diluted EPS for Q1FY26 was INR 26.84, against INR 37.32 in Q1FY25; net cash as of 30 June 2025 was INR 34,740 Mn. The presentation lists US Para IV product pipeline entries and early-stage NCE and cell and gene therapy investments, without management commentary on outlook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | dividend Capex, Dividend / buy-back, Results | Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on August 12, 2025, declared Interim Dividend of Rs.2 /-per equity share.AI summaryNATCO Pharma's board, meeting held 12 August 2025, approved unaudited standalone and consolidated results for the quarter ended 30 June 2025. Consolidated revenue from operations for Q1 FY26 was Rs 13,289 million, against Rs 13,626 million a year earlier; consolidated profit for the period was Rs 4,803 million, against Rs 6,685 million in the year-ago quarter. Board declared interim dividend of Rs 2 per equity share (100% on Rs 2 face value) for FY 2025-26, with record date 19 August 2025 and payment starting 26 August 2025. Board approved increase in authorised share capital to Rs 45,00,00,000 (22,50,00,000 equity shares of Rs 2 each), subject to shareholder approval, with consequential alteration of the Memorandum of Association. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | board outcome Capex, Dividend / buy-back, Results | Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryNATCO Pharma's board on 12 August 2025 approved unaudited standalone and consolidated results for the quarter ended 30 June 2025, with consolidated revenue from operations of Rs 13,289 million and consolidated profit for the period of Rs 4,803 million (versus Rs 6,685 million in the June 2024 quarter). The board declared an interim dividend of Rs 2 per equity share (100% on Rs 2 face value) for FY 2025-26, with record date 19 August 2025 and payment starting 26 August 2025. The board approved an increase in authorised share capital to Rs 45,00,00,000 (22,50,00,000 equity shares of Rs 2 each), subject to shareholder approval, with a corresponding change to Clause V of the Memorandum of Association. The board approved the notice for the 42nd Annual General Meeting, with the date and time to be fixed by the Chairman and Managing Director. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jul 2025 | transcript Acquisition, Capex | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNATCO Pharma filed the transcript of its conference call held on July 23, 2025 on the proposed investment in Adcock Ingram Holdings Limited. Management (CEO & Vice Chairman Rajeev Nannapaneni) said NATCO is proposing to acquire a 35.75% stake, with Bidvest holding 64.25%, at ZAR 75 per share, and that the company will be delisted; the cost is stated as about 2,000 crores. Management said Adcock Ingram had revenue of about US$536 million last year and about US$262 million in the half year, and that the transaction is expected to close in about 3-4 months. Management said NATCO has a first right of refusal on any future Bidvest stake sale, and that the company will consolidate its share of profits, with no current plans to sell the OTC or Consumer businesses. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jul 2025 | presentation Acquisition | Natco Pharma Limited has informed the Exchange about Investor PresentationAI summaryNATCO Pharma filed an investor presentation on a proposed investment in South Africa's Adcock Ingram, a subsidiary of The Bidvest Group Limited, with Bidvest holding 64.25% and NATCO 35.75% after the deal. Proposed price per share is ZAR 75 (US$ 4.271); cost to NATCO is ZAR 4 Bn (US$ 226 Mn), or ₹ 2,000 Cr, with transaction costs of about US$ 10 Mn. Adcock Ingram revenue was US$ 536 Mn in FY24 and US$ 262 Mn in H1 FY25 (Dec 2024), with EBITDA of US$ 78 Mn and net profit of US$ 45 Mn in FY24; transaction multiples are 7.83x EV/EBITDA and 1.12x revenue, based on FY24 figures. Adcock Ingram is described as the second-largest South African pharmaceutical company by private market share, with three manufacturing facilities near Johannesburg and a 49% stake in an Indian JV running two plants in India. NATCO's stated rationale includes South Africa as a gateway to the African continent and NATCO's existing front-ends in the USA, Canada, Brazil, Philippines, Singapore, Australia and Indonesia. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jul 2025 | board outcome Acquisition, Capex, Legal | Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 23, 2025.AI summaryNATCO Pharma's board, meeting held on 23 July 2025, approved acquiring 51,643,319 shares (35.75% including its prior 0.80% holding) of Adcock Ingram Holdings Limited, South Africa, at ZAR 75.00 per share, for a total investment cost of about Rs 2,000 crore. The board also approved incorporating a wholly owned subsidiary in South Africa, NATCO Pharma South Africa Proprietary Limited, with investment up to Rs 2,100 crore. The board approved liquidating its wholly owned subsidiary Time Cap Overseas Limited, which directly holds the investment in NatcoFarma do Brasil Ltda. The acquisition is subject to FEMA compliance, South Africa's Takeover Regulation Panel, South African Reserve Bank and other approvals, with completion expected on or before 31 December 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Jun 2025 | transcript Capex, Guidance, Legal, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNATCO Pharma filed the transcript of its Q4 and FY25 earnings conference call held on May 29, 2025. Management reported FY25 consolidated total revenue of INR4,784 crores (up about 16% from INR4,126.9 crores) and consolidated net profit of INR1,883.4 crores (up 36% from INR1,388.3 crores). Management said Q4 FY25 consolidated net revenue was INR1,287.3 crores (vs INR1,110.3 crores) and profit was INR406 crores (vs INR386.3 crores), including a INR50 crore impairment in Crop Health Science and a chargeback adjustment of about INR25 crores in its U.S. subsidiary. Management estimated FY26 revenue could dip about 20% and profit about 30%, citing U.S. pricing pressure, geopolitical uncertainty and higher R&D spend; it said FY25 R&D was INR373 crores and it targets up to INR400 crores in FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2025 | presentation Results | Natco Pharma Limited has informed the Exchange about Investor PresentationAI summaryNATCO Pharma filed its Q4 FY25 and FY25 earnings presentation for the quarter and year ended 31 March 2025. Q4 FY25 consolidated total revenue was INR 12,873 Mn (Q4 FY24: INR 11,103 Mn); Q4 FY25 EBITDA was INR 6,144 Mn at a 47.7% margin, and PAT was INR 4,060 Mn. FY25 consolidated total revenue was INR 47,840 Mn (FY24: INR 41,269 Mn); FY25 EBITDA was INR 25,505 Mn at a 53.3% margin, and PAT was INR 18,834 Mn (basic and diluted EPS INR 105.26). The presentation notes a Q4 FY25 impairment charge of INR 50 crore in the Crop Health Science business and a chargeback adjustment of about INR 25 crore in its US subsidiary. It also lists ANDA approvals for Bosentan tablets for oral suspension and Everolimus tablets for oral suspension, and a pipeline of over 20 first-to-file Para IV filings in the US. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2025 | board outcome Legal, Results | Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryBoard of NATCO Pharma Limited approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025 under Ind AS, along with auditor's reports (unmodified opinion). The Board approved appointment of BK & Associates, Practicing Company Secretaries, as Secretarial Auditors for five consecutive years from FY2025-26 to FY2029-30, subject to shareholder approval at the ensuing AGM. The Board re-constituted the Risk Management Committee. Board meeting commenced at 13:00 and concluded at 15:30 on May 28, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Feb 2025 | transcript Acquisition, Guidance, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNatco Pharma filed the transcript of its Q3 FY25 earnings conference call held on February 13, 2025. Management said consolidated total revenue was Rs 651.1 crore for the quarter ended December 31, 2024, against Rs 795.6 crore a year earlier, and consolidated net profit was Rs 132.4 crore against Rs 212.7 crore. Management said the quarter was soft because there was no Revlimid sale after the allocation was sold out by September end, and that a one-time pre-tax gain of about Rs 90 crore from a land sale was included in other income. Management said it expects about one-third of the Revlimid market allocation to start contributing from the next quarter and that the next few quarters will be good. Management said cash and liquid investments were Rs 3,264 crore against debt of about Rs 241 crore as of December 31, 2024, and that the company is looking at acquisitions. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2025 | presentation Dividend / buy-back, Legal, Results | Natco Pharma Limited has informed the Exchange about Investor PresentationAI summaryNATCO Pharma filed its Q3 FY25 earnings presentation for the quarter and nine months ended December 31, 2024. Q3 FY25 consolidated total revenue was INR 6,511 Mn (vs INR 7,956 Mn in Q3 FY24), EBITDA was INR 2,151 Mn with a 33.0% margin, and profit after tax was INR 1,324 Mn (vs INR 2,127 Mn in Q3 FY24). Pharma export formulations revenue was INR 2,858 Mn and domestic formulations revenue was INR 961 Mn in Q3 FY25. The Board declared a third interim dividend of INR 1.50 per equity share of INR 2 each. The presentation also notes a settlement between NATCO's partner Mylan Pharmaceuticals Inc. and Novo Nordisk of U.S. patent litigation on generic Ozempic (Semaglutide), and an ANDA filing with the U.S. FDA for generic EVRYSDI (Risdiplam) oral solution. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2025 | results Dividend / buy-back, Results | Integrated Filing - FinancialsAI summaryIntegrated filing (financial) for the quarter and nine months ended December 31, 2024, with unaudited consolidated results approved by the Board on 12 February 2025. Q3 FY25 consolidated revenue from operations was Rs 4,748 million, against Rs 13,711 million in Q2 FY25 and Rs 7,586 million in Q3 FY24; consolidated net profit (profit for the period) was Rs 1,324 million, against Rs 6,765 million in Q2 FY25 and Rs 2,127 million in Q3 FY24. Nine-month consolidated revenue from operations was Rs 32,085 million (Rs 29,305 million in the prior-year period); nine-month profit for the period was Rs 14,774 million (Rs 10,020 million); basic EPS for the nine months was Rs 82.56. The Board approved an interim dividend of Rs 1.5 per equity share (face value Rs 2) for the quarter ended 31-12-2024. The statutory auditors issued an unmodified review report on the results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2025 | results Dividend / buy-back, Management change, Results | Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryNATCO Pharma announced unaudited consolidated results for the quarter and nine months ended 31-12-2024: Q3 revenue from operations Rs 4,748 million (Rs 7,586 million in Q3 FY24), net profit Rs 1,324 million (Rs 2,127 million), basic EPS Rs 7.43; nine-month revenue Rs 32,085 million and net profit Rs 14,774 million. The Board declared a third interim dividend of Rs 1.50 per equity share (75%) of Rs 2 face value for FY 2024-25, with record date 18 February 2025 and payment starting 28 February 2025. Dr. Pavan Ganapati Bhat, Director and Executive Vice President (Technical Operations), resigned effective close of business on 12 February 2025 to take up a new career opportunity outside the company, and ceases as a member of the Risk Management Committee. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Nov 2024 | transcript Dividend / buy-back, Guidance, Results | Natco Pharma Limited has informed the Exchange about TranscriptAI summaryNATCO Pharma filed the transcript of its Q2 FY25 earnings conference call held on 13 November 2024, as required under Regulation 30 of the SEBI LODR Regulations. Management said consolidated total revenue for Q2 FY25 (quarter ended 30 September 2024) was INR 1,434.9 crores, against INR 1,060.8 crores a year earlier, a growth of 35.3%. Management reported consolidated net profit of INR 676.5 million for the quarter, against INR 369 crores a year earlier, growth of about 82%, and declared a second interim dividend of INR 1.5 per equity share for FY25. Management said it expects December quarter revenue to be weaker than Q2 and reiterated guidance of about 20% profitability (PAT) growth over last year, without giving a revenue figure. Management said Revlimid volumes are likely in the same range as Q1 and that it expects no challenges for Revlimid in FY25, while the semaglutide launch timeline is confidential. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.